Aurinia Pharmaceuticals INC

Aurinia Pharmaceuticals shareholders re-elected the board of directors and approved executive compensation at the 2026 annual meeting.

Aurinia Pharmaceuticals Inc. has successfully completed its acquisition of Kezar Life Sciences, Inc. through a tender offer and subsequent merger, with the transaction closing on May 11, 2026.

Aurinia Pharmaceuticals reported strong Q1 2026 financial results, with total revenue up 24% year-over-year, driven by significant growth in LUPKYNIS net product sales.

Aurinia Pharmaceuticals announced a definitive agreement to acquire Kezar Life Sciences for $6.955 in cash per share plus a contingent value right.

Aurinia Pharmaceuticals announced a significant leadership transition, appointing Kevin Tang as Chief Executive Officer and making other key executive changes.

Aurinia Pharmaceuticals announced robust financial results for Q4 and full-year 2025, driven by significant LUPKYNIS sales growth, and provided optimistic 2026 revenue guidance.

Aurinia Pharmaceuticals Inc. announced a significant increase in net product sales and improved operating income for the first quarter of 2026, driven by strong performance of LUPKYNIS.

Aurinia Pharmaceuticals Inc. announced significant increases in net product sales and net income for the third quarter and first nine months of 2025, driven by LUPKYNIS growth and strategic restructuring benefits.

Aurinia Pharmaceuticals Inc. announced a significant swing to profitability and robust revenue growth for the second quarter and first half of 2025, driven by increased LUPKYNIS sales and strategic cost reductions, alongside positive clinical data for its pipeline asset and an expanded share repurchase plan.

Aurinia Pharmaceuticals announces a 25% increase in net product sales for Q1 2025, driven by growing Lupkynis sales and market penetration.

Aurinia Pharmaceuticals reported its Q3 2024 financial results, highlighted by increased product revenue and a strategic restructuring aimed at focusing on LUPKYNIS growth and AUR200 development.

Aurinia Pharmaceuticals saw a significant increase in revenue in the second quarter of 2024, driven by higher sales of LUPKYNIS and a strategic restructuring.

Aurinia Pharmaceuticals announced a significant increase in net product sales for LUPKYNIS and a substantial rise in net income for the fiscal year ended December 31, 2025.

Aurinia Pharmaceuticals' 2024 10-K filing highlights a 36% increase in LUPKYNIS net product sales, strategic restructuring efforts, and ongoing development of AUR200.

Aurinia Pharmaceuticals has filed an amendment to its 2023 annual report, including previously omitted information and updating its financial outlook, highlighting a strategic shift towards commercial execution and cost reduction.

Aurinia Pharmaceuticals ends its strategic review, discontinues development of AUR200 and AUR300, and initiates a $150 million share repurchase program.

Aurinia Pharmaceuticals Inc. Director Craig A. Johnson acquired 23,931 stock options with an exercise price of $15.67, vesting one year from the grant date.

Aurinia Pharmaceuticals Inc. reports a stock option grant to Director Kathleen Goetz, with vesting details and exercise price.

Aurinia Pharmaceuticals Inc. reports a stock option grant to Director Tina Susan Nova, with vesting details and ownership information.

Aurinia Pharmaceuticals Director Jeffrey Allen Bailey acquired 23,931 stock options with an exercise price of $15.67.

CEO Kevin Tang and Tang Capital Management acquired over 814,000 shares of Aurinia Pharmaceuticals, signaling strong internal confidence in the company's value.

Chief Legal Officer Stephen P. Robertson was granted 115,541 performance stock units tied to future share price targets.

Aurinia Pharmaceuticals announces its 2026 Annual General Meeting to be held virtually on June 3, 2026, featuring director elections and executive compensation votes.

Leading independent proxy advisor Glass Lewis recommends Aurinia Pharmaceuticals shareholders vote in favor of all board proposals at the upcoming 2025 Annual General Meeting.

Aurinia Pharmaceuticals Inc. has filed a definitive proxy statement with the SEC related to its upcoming annual meeting.

Aurinia Pharmaceuticals seeks shareholder approval for an amendment to its Equity Incentive Plan and reports significant corporate governance changes, including a reduced board size and new director nominees.

Aurinia Pharmaceuticals addresses concerns regarding Lucien Selce's proposals, highlighting his background and lack of transparency, while reaffirming the company's strategic direction and recommending shareholders vote for the current board.

Aurinia Pharmaceuticals is reducing the proposed increase in shares reserved for issuance under its Equity Incentive Plan from 11,375,000 to 8,500,000 shares.

Tang Capital Management and Kevin Tang have increased their beneficial ownership in Aurinia Pharmaceuticals to 10.0%.

Kevin Tang, a significant beneficial owner, has been appointed Chief Executive Officer of Aurinia Pharmaceuticals Inc.

Tang Capital Management and affiliates have increased their beneficial ownership in Aurinia Pharmaceuticals Inc. to 9.2% through recent open market purchases totaling $26.3 million.

ILJIN SNT and Seoung Eun Huh reduce their beneficial ownership in Aurinia Pharmaceuticals, bringing the group's total stake to 5.0%.

Tang Capital Management and its affiliates have significantly increased their beneficial ownership in Aurinia Pharmaceuticals Inc., now holding 7.3% of the common shares after investing an additional $23.5 million.

Armistice Capital, LLC and Steven Boyd have jointly filed an amended Schedule 13G, reporting a beneficial ownership of 4.47% in Aurinia Pharmaceuticals Inc. as of December 31, 2024.